Amerigroup Stock Hits New 52-Week High (AGP)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Amerigroup Corporation (NYSE: AGP) hit a new 52-week high Friday as it is currently trading at $90.65, above its previous 52-week high of $90.41 with 68,432 shares traded as of 9:35 a.m. ET. Average volume has been 1.4 million shares over the past 30 days.

Amerigroup has a market cap of $4.37 billion and is part of the health care sector and health services industry. Shares are up 52.4% year to date as of the close of trading on Thursday.

AMERIGROUP Corporation operates as a multi-state managed healthcare company. The company has a P/E ratio of 30.9, equal to the average health services industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Amerigroup as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Amerigroup Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing